CABYR在胃癌组织中的异常表达及其临床意义

赵皓; 张文静; 杨子; 张小凤; 牛嘉琪; 宋雪

doi:10.16766/j.cnki.issn.1674-4152.003831

CABYR在胃癌组织中的异常表达及其临床意义

doi: 10.16766/j.cnki.issn.1674-4152.003831

赵皓¹,
张文静²,
杨子³,
张小凤^{1, 2},
牛嘉琪³,
宋雪^{1, 2, ,}

1.
蚌埠医科大学第一附属医院中心实验室，安徽蚌埠 233004
2.
炎症相关性疾病基础与转化研究安徽省重点实验室，安徽蚌埠 233004
3.
蚌埠医科大学第一附属医院胃肠外科

基金项目:

安徽省2020年度高校科学研究项目 KJ2020A056

详细信息

通讯作者:
宋雪，E-mail：songxue0214@bbmc.edu.cn

中图分类号: R735.2 R730.7
计量
- 文章访问数: 24
- HTML全文浏览量: 20
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2024-03-19
- 网络出版日期: 2025-02-13

Abnormal expression and clinical significance of CABYR in gastric cancer

ZHAO Hao¹,
ZHANG Wenjing²,
YANG Zi³,
ZHANG Xiaofeng^{1, 2},
NIU Jiaqi³,
SONG Xue^{1, 2
, ,}

1.
Department of Central Laboratory, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

摘要

摘要: 目的分析钙离子结合酪氨酸磷酸化调节基因(CABYR)在胃癌组织中的表达情况及与临床病理参数间的关系，并探讨其与胃癌患者远期预后的关系。方法利用癌症公共数据库分析CABYR在胃癌中的表达水平和对疾病进展及预后的影响，并纳入2017年1月—2018年4月在蚌埠医科大学第一附属医院接受根治术治疗的107例胃癌患者进行验证。另采用癌症公共数据库预测CABYR在胃癌中可能参与的生物学过程并进一步分析其与免疫细胞浸润的相关性。结果癌症公共数据库分析发现CABYR在胃癌组织中的表达水平显著高于癌旁组织，与胃癌临床分期密切相关，且CABYR高表达组患者术后生存期明显低于低表达组(P＜0.05)。本院临床病例分析发现，CABYR在胃癌组织中的表达水平较癌旁组织显著升高[(6.944±1.841) vs.(1.000±0.245)，P < 0.001]，与疾病恶性进展密切相关, 且CABYR高表达组患者术后5年生存率较低表达组显著降低(log-rank χ²=32.799，P＜0.05)。Cox回归分析显示CABYR高表达是影响患者术后5年生存率的独立危险因素(HR=2.985，95% CI：1.460~6.104)，ROC曲线分析显示CABYR预测患者癌性死亡的灵敏度为80.39%，特异度为73.21%(P＜0.05)。此外，癌症公共数据库分析发现CABYR在胃癌中的生物功能主要与免疫细胞的浸润有关。结论 CABYR在胃癌中高表达并与胃癌疾病进展密切相关，可作为评估患者临床预后的生物学标记物。
- 胃癌 /
- CABYR /
- 预后 /
- 免疫浸润 /
- 肿瘤标志物
Abstract: Objective To investigate the expression of calciumbinding tyrosine phosphorylation-regulated gene (CABYR) in gastric cancer tissues and its relationship with clinicopathological parameters, and to explore its relationship with the long-term prognosis of gastric patient. Methods The expression level of CABYR in gastric cancer was analyzed using public cancer databases to assess its impact on disease progression and prognosis. Additionally, 107 gastric cancer patients who underwent radical surgery at the First Affiliated Hospital of Bengbu Medical University from January 2017 to April 2018 were included for validation. Furthermore, the potential biological processes involving CABYR in gastric cancer were predicted using public cancer databases, and its correlation with immune cell infiltration was further analyzed. Results Analysis of public cancer databases revealed that the expression level of CABYR in gastric cancer tissue was significantly higher than that in adjacent non-cancerous tissue and was closely associated with clinical staging. Moreover, patients with high CABYR expression had significantly lower postoperative survival rates compared to those with low expression (P < 0.05). In the clinical validation, the expression level of CABYR in gastric cancer tissue was significantly elevated compared to adjacent non-cancerous tissue [(6.944±1.841) vs. (1.000±0.245), P < 0.001], correlating strongly with malignant disease progression. Additionally, the 5-year postoperative survival rate of patients with high CABYR expression was significantly lower compared to the low-expression group (log-rank χ²=32.799, P < 0.05). Cox regression analysis showed that high CABYR expression as an independent risk factor for reduced 5-year postoperative survival (HR=2.985, 95% CI: 1.460-6.104). ROC curve analysis demonstrated that CABYR predicted cancer-related death with 80.39% sensitivity and 73.21% specificity (P < 0.05). Further database analysis revealed that the biological function of CABYR in gastric cancer was mainly associated with immune cell infiltration. Conclusion High expression of CABYR is closely associated with gastric cancer progression and can serve as a biomarker for evaluating clinical prognosis.
- Gastric cancer /
- CABYR /
- Prognosis /
- Immune infiltration /
- Tumor biomarker

HTML全文

图 1 胃癌组织中CABYR的表达情况

注：A为免疫组织化学技术检测CABYR在胃癌和癌旁组织中的表达情况；B为TCGA数据库分析CABYR在不同类型肿瘤中的mRNA表达水平。^aP < 0.001，^bP < 0.01。

Figure 1. Expression of CABYR in gastric cancer

下载: 全尺寸图片幻灯片

图 2 胃癌中CABYR蛋白表达与临床分期之间的关系

Figure 2. The relationship between the expression of CABYR protein and clinicopathological parameters in gastric cancer

下载: 全尺寸图片幻灯片

图 3 CABYR蛋白表达与胃癌患者预后的关系

注：A为Kaplan-Meier生存分析CABYR表达量对患者术后生存率的影响；B为Kaplan-Meier数据库分析CABYR表达量与患者总生存期的关系。

Figure 3. Relationship between CABYR protein expression and prognosis in gastric cancer patients

下载: 全尺寸图片幻灯片

图 4 CABYR评估胃癌患者术后预后的ROC曲线

Figure 4. ROC curve of postoperative prognosis in gastric cancer patients assessed by CABYR

下载: 全尺寸图片幻灯片

图 5 GO和KEGG富集分析结果

注：A为GO-BP富集分析CABYR可能的生物学功能；B为KEGG富集分析CABYR相关的信号通路。

Figure 5. Results of GO and KEGG enrichment analysis

下载: 全尺寸图片幻灯片

表 1 胃癌中CABYR蛋白表达与临床病理参数之间的关系(例)

Table 1. Relationship between the expression of CABYR protein and clinicopathological parameters in gastric cancer(cases)

临床病理参数	例数	低表达组 (n=53)	高表达组 (n=54)	χ²值	P值
性别				0.002	0.961
女性	22	11	11
男性	85	42	43
年龄(岁)				1.587	0.208
＜60	44	25	19
≥60	63	28	35
病理类型				0.717	0.397
腺癌	81	42	39
其他	26	11	15
脉管浸润				15.729	< 0.001
无	50	35	15
有	57	18	39
肿瘤最大径(cm)				0.225	0.635
＜5	40	21	19
≥5	67	32	35
组织学分级				0.255	0.613
G1~G2级	62	32	30
G3级	45	21	24
T分期				11.525	0.001
T1~T2期	57	37	20
T3~T4期	50	16	34
N分期				5.042	0.025
N0~N1期	59	35	24
N2~N3期	48	18	30
TNM分期				18.918	< 0.001
Ⅰ期~Ⅱ期	52	37	15
Ⅲ期~Ⅳ期	55	16	39

下载: 导出CSV

表 2 胃癌患者胃癌根治术后5年生存率的影响因素分析

Table 2. Analysis of risk factors affecting 5-year survival rate after radical gastrectomy

临床病理参数	单因素		多因素
临床病理参数	log-rank χ²值	P值	HR值(95% CI)	P值
性别(男性vs. 女性)	0.204	0.652
年龄(＜60岁vs. ≥60岁)	1.259	0.262
病理类型(腺癌vs. 其他)	0.836	0.361
脉管浸润(无vs. 有)	42.838	< 0.001	3.956(1.774~8.819)	0.001
肿瘤直径(＜5 cm vs. ≥5 cm)	0.001	0.971
组织学分级(G1~G2 vs. G3)	0.035	0.852
浸润深度(T1~T2 vs. T3~T4)	27.389	< 0.001	2.653(1.373~5.126)	0.004
淋巴结转移(N0~N1 vs. N2~N3)	22.388	< 0.001	2.394(1.254~4.571)	0.008
TNM分期(Ⅰ期~Ⅱ期vs. Ⅲ期~Ⅳ期)	37.810	< 0.001	3.058(1.427~6.554)	0.004
CABYR表达(低vs. 高)	32.799	< 0.001	2.985(1.460~6.104)	0.003
注：各变量赋值方法如下，无脉管浸润=0，有脉管浸润=1；浸润深度，T1~T2=0，T3~T4=1；淋巴结转移，N0~N1=0，N2~N3=1；TNM分期，Ⅰ期~Ⅱ期=0，Ⅲ期~Ⅳ期=1；CABYR低表达=0，CABYR高表达=1。

下载: 导出CSV

表 3 CABYR与胃癌免疫细胞浸润水平的相关性分析

Table 3. Correlation analysis of CABYR expression and immune cell infiltration in gastric cancer

免疫细胞	r值	P值
CD4⁺ T Cell	0.137	0.009
Macrophage	0.119	0.022
CD8⁺ T Cell	-0.144	0.005
Neutrophil	-0.130	0.012

下载: 导出CSV

参考文献(16)

[1]	SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635-648. doi: 10.1016/S0140-6736(20)31288-5
[2]	赵天豪, 杨一群, 李岳彤, 等. 泛素结合酶2S在胃癌中的表达及临床意义[J]. 中华全科医学, 2023, 21(4): 555-559. ZHAO T H, YANG Y Q, LI Y T, et al. Expression and clinical significance of UBE2S in gastric cancer[J]. Chinese Journal of General Practice, 2023, 21(4): 555-559.
[3]	LORDICK F, CARNEIRO F, CASCINU S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(10): 1005-1020. doi: 10.1016/j.annonc.2022.07.004
[4]	JOSHI S S, BADGWELL B D. Current treatment and recent progress in gastric cancer[J]. CA Cancer J Clin, 2021, 71(3): 264-279. doi: 10.3322/caac.21657
[5]	PELLONI M, PAOLI D, MAJOLI M, et al. Molecular study of human sperm RNA: ropporin and CABYR in asthenozoospermia(Article)[J]. J Endocrinol Invest, 2018, 41(7): 781-787. doi: 10.1007/s40618-017-0804-x
[6]	KUMARA H M, SUTTON E, CABALLERO O L, et al. The cancer testis antigens CABYR-a/b and CABYR-c are expressed in a subset of colorectal cancers and hold promise as targets for specific immunotherapy[J]. Oncotarget, 2021, 12(5): 412-421. doi: 10.18632/oncotarget.27897
[7]	YU X N, GUO H Y, LIU T T, et al. Upregulated calcium-binding tyrosine phosphorylation-regulated protein-a/b regulates cell proliferation and apoptosis and predicts poor prognosis in hepatocellular carcinoma[J]. J Cell Biochem, 2020, 121(4): 2938-2949. doi: 10.1002/jcb.29538
[8]	杨子, 张浩, 徐梦宇, 等. 胃癌中MLF1IP表达的预后价值及其对肿瘤进展的调控作用[J]. 四川大学学报(医学版), 2023, 54(1): 114-121. YANG Z, ZHANG H, XU M Y, et al. Prognostic Value of the Expression of Myeloid Leukemia Factor 1-Interacting Protein in Gastric Cancer and Its Regulatory Role in Tumor Progression[J]. Journal of Sichuan University(Medical Sciences), 2023, 54(1): 114-121.
[9]	AJANI J A, D ' AMICO T A, BENTREM D J, et al. Gastric cancer, version 2. 2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(2): 167-192. doi: 10.6004/jnccn.2022.0008
[10]	封雪, 王咏强, 赵滨滨. 七氟醚调控miR-4458影响胃癌SNU-1细胞的增殖、迁移和凋亡[J]. 河北医药, 2021, 43(24): 3695-3699. doi: 10.3969/j.issn.1002-7386.2021.24.003 FENG X, WANG Y Q, ZHAO B B. Effects of sevoflurane on the proliferation, migration and apoptosis of gastric cancer SNU-1 cells by regulating miR-4458[J]. Hebei Medical Journal, 2021, 43(24): 3695-3699. doi: 10.3969/j.issn.1002-7386.2021.24.003
[11]	SONG Z Y, WU Y Y, YANG J B, et al. Progress in the treatment of advanced gastric cancer[J]. Tumour Biol, 2017, 39(7): 10.1177/1010428317714626. DOI: 10.1177/1010428317714626.
[12]	SHEN J J, WANG Z M. Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: a review[J]. Front Oncol, 2022, 12: 934249. DOI: 10.3389/fonc.2022.934249.
[13]	LI K X, ZHANG A, LI X Y, et al. Advances in clinical immunotherapy for gastric cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2): 188615. DOI: 10.1016/j.bbcan.2021.188615.
[14]	KUMARA H, SUTTON E, CABALLERO O L, et al. The cancer testis antigens CABYR-a/b and CABYR-c are expressed in a subset of colorectal cancers and hold promise as targets for specific immunotherapy[J]. Oncotarget, 2021, 12(5): 412-421. doi: 10.18632/oncotarget.27897
[15]	韩涛, 夏文彬, 吕扬, 等. 胃癌不同部位特征和预后的对比分析及临床意义[J]. 中国肿瘤临床, 2020, 47(23): 1200-1204. HAN T, XIA W B, LYU Y, et al. Comparative analysis of the features and prognoses of gastric cancer at different sites[J]. Chinese Journal of Clinical Oncology, 2020, 47(23): 1200-1204.
[16]	FUTAWATARI N, FUKUYAMA T, YAMAMURA R, et al. Early gastric cancer frequently has high expression of KK-LC-1, a cancer-testis antigen[J]. World J Gastroenterol, 2017, 23(46): 8200-8206. doi: 10.3748/wjg.v23.i46.8200